Central India Chronicle

Diffuse Large B-Cell Lymphoma Emerging Drugs, 2020

 Breaking News
  • No posts were found

Diffuse Large B-Cell Lymphoma Emerging Drugs, 2020

September 02
15:01 2020
Diffuse Large B-Cell Lymphoma Emerging Drugs, 2020

DelveInsight Business Research LLP
Diffuse Large B-cell Lymphoma Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diffuse Large B-cell Lymphoma market. A detailed picture of the Diffuse Large B-cell Lymphoma pipeline landscape is provided, which includes the disease overview and Diffuse Large B-cell Lymphoma treatment guidelines.

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that affects B-lymphocytes. It develops when B-lymphocytes become abnormal. It is a mature B-cell neoplasm arising from the germinal center and post germinal center B-cells.

 

Diffuse Large B-Cell Lymphoma Emerging Drugs

  1. Lisocabtagene maraleucel: Bristol-Myers Squibb
  2. Brentuximab Vedotin: Seattle Genetics/Takeda
  3. Loncastuximab Tesirine: ADC Therapeutics
  4. Tafasitamab: Morphosys/Incyte
  5. Treakisym: SymBio Pharmaceuticals
  6. Enzastaurin (DB102): Denovo Biopharma
  7. Ublituximab + Umbralisib: TG Therapeutics
  8. Blinatumomab: Amgen
  9. Aliqopa (Copanlisib/BAY 80-6946): Bayer
  10. Imbruvica (Ibrutinib): Janssen/Pharmacyclics (AbbVie Company)
  11. Odronextamab (REGN1979): Regeneron Pharmaceuticals
  12. Imfinzi (durvalumab): Celgene/Bristol Myers Squibb
  13. Parsaclisib (INCB050465): Incyte Corporation
  14. TC 110: TCR2 Therapeutics
  15. DPX-Survivac: IMV, inc. & Merck
  16. Acalabrutinib: AstraZeneca
  17. AUTO3: Autolus Therapeutics
  18. Obinutuzumab: Hoffmann-La Roche
  19. CLR 131: Cellectar Bioscience
  20. Debio1562: Debiopharm International

 

The dynamics of the DLBCL therapeutic market is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Key players, such as MorphoSys, Cellectar, ADC Therapeutics, and others are involved in developing drugs for DLBCL.

MOR208 (MorphoSys) also known as Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19, which is assumed to be involved in B cell receptor (BCR) signaling. MorphoSys is clinically investigating MOR208 as a therapeutic option in B cell malignancies in several combination trials. The MOR208 in combination with lenalidomide; bendamustine is being investigated individually in patients with relapsed/refractory DLBCL who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) in the phase II/III trial. Based on interim data from L-MIND study, the FDA granted Breakthrough Therapy Designation for MOR208 plus lenalidomide in this patient population. Along with this, Orphan drug designation was received for MOR208 for the indications of DLBCL and CLL/SLL from FDA and EMA.

ADCT-402 (ADC Therapeutics) also known as loncastuximab tesirine is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody that binds to human CD19, conjugated through a linker to a pyrrolobenzodiazepine (PBD)-dimer toxin. CD19 is an ideal target for an ADC approach, as it is highly expressed in a range of B-cell hematological tumors, including certain types of lymphoma and leukemia. Once bound to a CD19-expressing cell, it internalized into the cell where enzymes release the PBD-based warhead. The FDA has granted orphan drug designation to ADCT-402 for the treatment of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). The ADC Therapeutics is currently conducting Phase II clinical trial in patients with relapsed or refractory (R/R), Phase I trial in combination with ibrutinib; and durvalumab in patients with R/R DLBCL or follicular lymphoma and melanoma.

Selinexor (Karyopharm Therapeutics) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound and functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. The FDA granted Fast Track designation to Selinexor for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies and are not eligible for high dose chemotherapy with stem cell rescue or CAR-T therapy. FDA has granted Selinexor orphan designation for both multiple myeloma and DLBCL.

CLR 131 (Cellectar) is a small-molecule, targeted Phospholipid Drug Conjugate (PDC) designed to deliver cytotoxic radiation directly and selectively to cancer cells. It is a lead therapeutic PDC product candidate of Cellectar. Currently, company is conducting the Phase II trial for the treatment of Diffuse Large B Cell Lymphoma and other indications such as Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and others. 

Scope of the report

  • The Diffuse Large B-cell Lymphoma report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Diffuse Large B-cell Lymphoma across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Diffuse Large B-cell Lymphoma therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Diffuse Large B-cell Lymphoma research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Diffuse Large B-cell Lymphoma.

 

Request for sample pages
Table of contents

1. Report Introduction

2. Diffuse Large B-cell Lymphoma 

2.1. Overview

2.2. History 

2.3. Diffuse Large B-cell Lymphoma Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Diffuse Large B-cell Lymphoma Diagnosis 

2.6.1. Diagnostic Guidelines

3. Diffuse Large B-cell Lymphoma Current Treatment Patterns

3.1. Diffuse Large B-cell Lymphoma Treatment Guidelines

4. Diffuse Large B-cell Lymphoma – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Diffuse Large B-cell Lymphoma companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Diffuse Large B-cell Lymphoma Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Diffuse Large B-cell Lymphoma Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Diffuse Large B-cell Lymphoma Late Stage Products (Phase-III)

7. Diffuse Large B-cell Lymphoma Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Diffuse Large B-cell Lymphoma Discontinued Products

13. Diffuse Large B-cell Lymphoma Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition 

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report? 

14. Diffuse Large B-cell Lymphoma Key Companies

15. Diffuse Large B-cell Lymphoma Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Diffuse Large B-cell Lymphoma Unmet Needs

18. Diffuse Large B-cell Lymphoma Future Perspectives

19. Diffuse Large B-cell Lymphoma Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles